| Patient | Joe Louis |
|---|---|
| Date of birth | 1971-05-13 |
| Identifiers | MRN HR-BX002-SYN; SSN (made up) 000-02-6639 |
| Document date | 2026-10-26 |
| Author | Desmond Achterberg-Cole, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fifteen-week review off the antipsychotic. [S]
Mr. Louis returns five weeks after his ten-week review. He finished the aripiprazole taper three weeks ago and has had no persecutory thoughts and no trouble sleeping. He completed twelve weeks of contingency management: 22 of 24 scheduled tests were done and 21 were negative, the positive one after his single day of use; he has had no cocaine since. On his trip last month he tested at a partner clinic and had his therapy session by phone. He will continue weekly therapy and a weekly urine test for now. His home readings average 124/78 mmHg. The tax clinic reviewed his records and found nothing owed; with the social worker he has a budget and has applied for veterans' health benefits. He would like his zoster and second hepatitis B vaccines today. [S]
| Element | Detail |
|---|---|
| Cocaine | None for eight weeks |
| Contingency management | Twelve weeks completed; 21 of 22 tests negative |
| Aripiprazole | Stopped three weeks ago; no return of symptoms |
| Home blood pressure | Average 124/78 mmHg |
| Finances | Nothing owed; budget; veterans' benefits applied for |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Neurological | Negative | No headaches or memory lapses |
| Psychiatric | Negative | No persecutory thoughts; sleeping well; no thoughts of suicide or of harming anyone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-07-13 | active | S |
| Aripiprazole 5 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-07-20 to 2026-09-21 | completed | S |
| Aripiprazole 2 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 2026-09-21 to 2026-10-05 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-08-10 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril as needed for congestion | Two sprays in each nostril up to every 4 hours as needed | Nasal route | 2026-08-03 to 2026-08-08 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for sore throat or aches, no more than 3,000 mg a day | One or two tablets every 6 hours as needed, no more than 3,000 mg a day | Oral route | 2026-08-03 to 2026-08-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 187 | cm | S |
| 2026-10-26 | Body weight | 101.6 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 72 | /min | S |
| 2026-10-26 | Respiratory rate | 16 | /min | S |
| 2026-10-26 | Body temperature | 36.7 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 78 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 72; weight 101.6 kg, BMI 29.1 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | No abnormal movements |
| Psychiatric | Relaxed; no delusional content |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persecutory thoughts and poor sleep for about two months: a fixed belief that people are following him and plan to harm him, three to four hours of sleep a night, partial insight; cause under evaluation | resolved | confirmed | R41.89 | S — Synthetic presenting problem anchored to his documented fears of a plot against his life; resolved into the diagnosis at the consultation. Not a claim about his real symptoms. |
| Cocaine use disorder, severe (seven of eleven DSM-5-TR criteria): intranasal cocaine most days for about a year, last use three days before intake | resolved | confirmed | F14.20 | S — Synthetic modern coding at intake; superseded at the consultation by the combined code once the psychotic disorder was diagnosed. Person-first language; not a claim about his real diagnosis. |
| Cocaine use disorder, severe, with cocaine-induced psychotic disorder (persecutory delusions during heavy use, persisting ten days after the last use, with no history of psychosis off cocaine, a normal examination and no evidence of a neurocognitive disorder); psychotic symptoms resolved within four weeks on aripiprazole | active | confirmed | F14.250 | S — Synthetic modern diagnosis made at the consultation. Not a claim about his real diagnosis. |
| Raised blood pressure at intake (154/98 mmHg) three days after cocaine use, without a diagnosis of hypertension; home readings planned | resolved | confirmed | R03.0 | S — Synthetic presenting finding; resolved into a diagnosis of hypertension at four weeks. |
| Hypertension, stage 2, confirmed four weeks after the last cocaine use (clinic 146/92, home average 144/90 mmHg), with mild concentric left ventricular hypertrophy and a normal aortic root on echocardiography; treated with amlodipine | active | confirmed | I10 | S — Synthetic modern diagnosis made at the four-week visit. |
| Financial insecurity: years of tax debt from his time as a well-paid athlete, now settled, left him with no savings; irregular income from paid appearances; worry about money keeps him awake | active | confirmed | Z59.86 | S — Synthetic social need anchored to his documented tax debt. |
| Acute viral upper respiratory infection (common cold) for three days; rapid tests negative for influenza and COVID-19; resolved within ten days without antibiotics | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Cocaine use since the last visit (his own account), cravings and triggers | Every visit | Completed today | No cocaine for eight weeks |
| Laboratory | Urine drug tests in contingency management, with fentanyl, and prize draws for negative results | Twice weekly for twelve weeks, then at visits | Completed today | Twelve weeks completed: 22 of 24 scheduled tests done, 21 negative; weekly tests continue |
| Examination | Psychotic symptoms, insight and sleep | Every visit | Completed today | No psychotic symptoms three weeks after stopping aripiprazole |
| Medication safety | Antipsychotic safety: weight, blood pressure, akathisia (Barnes scale) and abnormal movements (AIMS) | Weight and akathisia at every visit while on treatment; AIMS at baseline and every six months | Not indicated | Aripiprazole stopped three weeks ago; weight 101.6 kg, back near baseline; no abnormal movements |
| Laboratory | Fasting glucose or hemoglobin A1c and lipids on an antipsychotic | Baseline, at four months, then yearly | Not indicated | Off aripiprazole before the four-month check; lipids and hemoglobin A1c will be repeated yearly for his cardiovascular risk |
| Examination | Blood pressure in clinic and at home | Every visit; home readings before diagnosis and after each change | Completed today | Clinic 126/78; home average 124/78 mmHg; at target |
| Laboratory | Basic metabolic panel on antihypertensive treatment | Yearly, or after a change | Completed today | Sodium 140, potassium 4.3 mmol/L, creatinine 1.12 mg/dL, eGFR 78, glucose 92 mg/dL |
| Survey | Suicide and violence risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone |
| Medication safety | Naloxone and fentanyl test strips on hand | Every visit | Completed today | Naloxone and test strips still at home |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and every four weeks while in treatment | Completed today | PHQ-9 3, item 9 scored 0; GAD-7 4 |
| Self-management | Cognitive behavioral therapy | Weekly | Completed today | Thirteen sessions so far, one by phone while traveling |
| Self-management | Finances, social work and taxpayer services | Every visit | Completed today | Nothing owed on review; budget in place; veterans' benefits applied for |
| Self-management | Family involvement, only with his consent | Every visit | Completed today | He has chosen to tell his family about his recovery himself; no clinic contact requested |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), second of two doses; Recombinant zoster vaccine, first of two doses [S]
Guideline basis: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (2020); Treatment for Stimulant Use Disorders (Treatment Improvement Protocol 33, updated 2021) (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Zoster vaccine and second hepatitis B dose given today. Review in three months; second zoster dose in two to six months; second hepatitis A dose in four months. Weekly therapy and urine tests. Call the clinic or 988 at any time. [S]